Eye on Medication Access: JDNPPA’s Biosimilar News Roundup
Biocon Biologics’ Stelara Biosimilar Performs Well in Phase 3 Plaque PsO Study Yesintek, Biocon Biologics’ ustekinumab biosimilar, demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics with reference product Stelara (ustekinumab) in adults with moderate-to-severe chronic plaque psoriasis (PsO). The data were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. The […]